AbbVie Inc. vs Johnson & Johnson
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
In short
- Johnson & Johnson is the larger company by market value: $652.5 B against $514.0 B for AbbVie Inc., 1.3 times as much (market caps of Oct 30, 2026 for AbbVie Inc. and Oct 29, 2026 for Johnson & Johnson).
- Johnson & Johnson had more revenue: $94.2 B against $61.2 B for AbbVie Inc., both in the year to December 2025.
- Johnson & Johnson earned more: net income of $26.8 B against $4.2 B for AbbVie Inc.
- Johnson & Johnson keeps more of each dollar of sales: a net margin of 28.5% against 6.9% for AbbVie Inc.
- Johnson & Johnson employs more people: 138,200 against 57,000 at AbbVie Inc. Each employee brings in about $1,072,982 of revenue at AbbVie Inc. and $681,570 at Johnson & Johnson.
- On price to earnings, AbbVie Inc. trades at 49.7× and Johnson & Johnson at 40.5×: investors pay more for each dollar of AbbVie Inc.'s profit.
Market value, the same start = 100
From Jan 2020: how each one's value moved, whatever its size.
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | AbbVie Inc. ABBV · #26 in the world | Johnson & Johnson JNJ · #23 in the world |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceutical | Pharmaceutical |
| Founded | 2013 | 1886 |
| Size | ||
| Market cap | $514.0 B | $652.5 B |
| Revenue | $61.2 B | $94.2 B |
| Net income | $4.2 B | $26.8 B▲ best |
| Employees | 57,000 | 138,200 |
| Valuation | ||
| P/E ratio | 49.7× | 40.5× |
| Price to sales | 7.8× | 6.6× |
| Price to book | — | 8.0× |
| Free cash flow yield | 3.5%▲ best | 3.0% |
| Profitability | ||
| Gross margin | 70.2% | — |
| Operating margin | 24.6% | — |
| Net margin | 6.9% | — |
| Return on invested capital | 16.0% | — |
| Growth | ||
| Revenue growth | 8.6% | — |
| Revenue growth, 3 years a year | 1.8% | — |
| Earnings per share growth | -1.3% | — |
| Financial strength | ||
| Interest cover | 5.2× | — |
| Cash | ||
| Free cash flow margin | 29.1% | — |
| Shareholder returns | ||
| Dividend yield | 2.3% | — |
| Shareholder yield | 2.5% | — |
| Strength scores | ||
| Piotroski F-score | 8 of 9 | — |
| Altman Z-score zone | grey | — |
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap Oct 2026 |
▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither
Questions and answers#
Which is bigger, AbbVie Inc. or Johnson & Johnson?
Johnson & Johnson is the larger company by market value: $652.5 B against $514.0 B for AbbVie Inc., 1.3 times as much (market caps of Oct 30, 2026 for AbbVie Inc. and Oct 29, 2026 for Johnson & Johnson).
Which makes more money, AbbVie Inc. or Johnson & Johnson?
Johnson & Johnson had more revenue: $94.2 B against $61.2 B for AbbVie Inc., both in the year to December 2025. Johnson & Johnson earned more: net income of $26.8 B against $4.2 B for AbbVie Inc.
Which is more profitable, AbbVie Inc. or Johnson & Johnson?
Johnson & Johnson keeps more of each dollar of sales: a net margin of 28.5% against 6.9% for AbbVie Inc.
Which has more employees, AbbVie Inc. or Johnson & Johnson?
Johnson & Johnson employs more people: 138,200 against 57,000 at AbbVie Inc. Each employee brings in about $1,072,982 of revenue at AbbVie Inc. and $681,570 at Johnson & Johnson.
Is AbbVie Inc. cheaper than Johnson & Johnson?
On price to earnings, AbbVie Inc. trades at 49.7× and Johnson & Johnson at 40.5×: investors pay more for each dollar of AbbVie Inc.'s profit. A lower multiple is not by itself a better buy: it also reflects expected growth, risk and accounting.
More about AbbVie Inc.
More about Johnson & Johnson
Sources#
Every figure on this page comes from these, with the date shown next to it.